Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the June 15, 2022 Annual Meeting of Stockholders (the "Annual Meeting") of Bellicum Pharmaceuticals, Inc. (the "Company"), the Company's stockholders, upon the recommendation of the Company's Board of Directors, approved an amendment to the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (the "2019 Plan"), as set forth in an amended 2019 Plan (the "Amended 2019 Plan"). The material terms of the Amended 2019 Plan are the same as the 2019 Plan, except that the Amended 2019 Plan contains the following material changes to the 2019 Plan: (i) an increase to the number of shares of common stock authorized for issuance under the 2019 Plan by 2,250,000 shares; and (ii) a corresponding increase to the number of shares of common stock authorized for issuance under the 2019 Plan pursuant to the exercise of incentive stock options by 4,500,000 shares.

The Amended 2019 Plan became effective on June 15, 2022 upon stockholder approval at the Annual Meeting. A more detailed summary of the material features of the Amended 2019 Plan is set forth in the Company's definitive proxy statement on Schedule 14A for the Annual Meeting, filed with the Securities and Exchange Commission on April 29, 2022 (the "Proxy Statement"). Such summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2019 Plan, which is attached as Exhibit 10.1 hereto.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final voting results with respect to each matter:

Proposal 1. Election of Directors

The Company's stockholders elected the person listed below as a Class II Director, to serve until the Company's 2025 annual meeting of stockholders and until their successor is duly elected and qualified. The final voting results are as follows: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Judith Klimovsky, M.D. 1,723,047 152,813

              2,985,038

Proposal 2. Approval of the Plan Amendment

The Company's stockholders approved the Amended 2019 Plan. The final voting results were as follows:


    Votes For       Votes Against       Abstentions        Broker Non-Votes
    1,617,290          255,718             2,852              2,985,038

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company's Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:


    Votes For       Votes Against       Abstentions
    4,480,357          135,697            244,844

Proposal 4. Advisory Vote on Executive Compensation

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows:

--------------------------------------------------------------------------------

Votes For Votes Against Abstentions Broker Non-Votes


    1,569,503          292,255             14,102             2,985,038

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits
Exhibit Number          Description

10.1                      Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended.

104                     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses